|
Report ID
|
2761 |
|
Drug Identification Number
|
02212358 |
|
Brand name
|
ZANTAC |
|
Common or Proper name
|
Ranitidine tablets |
|
Company Name
|
GLAXOSMITHKLINE INC |
|
Market Status
|
CANCELLED POST MARKET |
|
Active Ingredient(s)
|
RANITIDINE |
|
Strength(s)
|
300MG |
|
Dosage form(s)
|
TABLET |
|
Route of administration
|
ORAL |
|
Packaging size
|
60's |
|
Anatomical Therapeutical Chemical (ATC) code
|
A02BA |
|
Anatomical Therapeutical Chemical (ATC) description
|
DRUGS FOR PEPTIC ULCER AND GASTROESOPHAGEAL REFLUX DISEASE (GERD) |
|
Reason for shortage
|
Disruption of the manufacture of the drug. |
|
Anticipated start date
|
|
|
Actual start date
|
2017-04-19 |
|
Estimated end date
|
|
|
Actual end date
|
2017-09-14 |
|
Shortage status
|
Resolved |
|
Updated date
|
2020-02-27 |
|
Company comments
|
This product has been discontinued. |
|
Health Canada comments
|
|
|
Tier 3 Status
|
No |
| Company contact information |
1-800-387-7374 |
